European Headache Alliance

Monthly Archives: June 2018

11.3% of Spanish adolescents suffer from migraine headaches

The journal Cephalalgia – the scientific publication of the International Society of Headaches – has just published a study by members of the Headache Study Group of the Spanish Society of Neurology (SEN) of the Vall D'Hebron University Hospital, whose Objective was to evaluate the prevalence of a headache among the Spanish adolescent population. Carried…
Read More

Why are migraine patients skipping effective behavioral treatments?

Effective behavioral treatments for migraine are being eschewed by a significant number of sufferers, according to a new study led by headache researchers at NYU School of Medicine. Researchers found that about half of migraine patients who were referred by a headache center for specific behavioral treatment did not follow through with therapy. This occurred…
Read More

How to take care of your diet if you suffer migraine

30 DE MAYO DE 2018 If we pay attention to what we eat, we can contribute to keeping headaches as far away from our lives as possible. If you have migraines, you probably know that maintaining a healthy lifestyle and respecting food and sleep schedules are two fundamental elements to keep them under control. But…
Read More

Novartis’ Migraine prevention therapy is closer to being approved

Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes…
Read More

First monoclonal antibody therapy for prevention of migraine

First monoclonal antibody therapy for prevention of Migraine Aimovig recommended for marketing authorization 01/06/2018 The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Aimovig (erenumab), the first human monoclonal antibody therapy for prevention of migraine. Aimovig belongs to a new class of medicines that work by blocking the activity…
Read More